Sorrento to partner with Nantworks founder Patrick Soon-Shiong on immunomodulatory antibodies

15 December 2014
2019_biotech_test_vial_discovery_big

Oncology specialist Sorrento Therapeutics (Nasdaq: SRNE) has entered into a binding agreement with medical technology company NantWorks founder, Patrick Soon-Shiong.

NantWorks and Sorrento will establish a global strategic collaboration to jointly develop immunotherapies for the treatment of cancer and auto-immune diseases. NantWorks, through a subsidiary, and Sorrento, intend to establish the first joint venture – "The Immunotherapy Antibody JV" – as an independent biotechnology company with $20 million initial joint funding.

Dr Soon-Shiong’s affiliated entity will acquire a 19.9% equity stake in Sorrento through the purchase of common stock at $5.80 per share, which was Sorrento’s closing share price on December 12. Sorrento also granted Dr Soon-Shiong a three-year warrant to purchase 1,724,138 shares of common stock at an exercise price of $5.80 per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology